- Home
- PLX vs ME Comparison
PLX vs ME Comparison
Compare PLX & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ME
- Stock Information
- Founded
- PLX 1993
- ME 2006
- Country
- PLX Israel
- ME United States
- Employees
- PLX N/A
- ME N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ME Precision Instruments
- Sector
- PLX Health Care
- ME Health Care
- Exchange
- PLX Nasdaq
- ME Nasdaq
- Market Cap
- PLX 132.5M
- ME 113.9M
- IPO Year
- PLX 1998
- ME N/A
- Fundamental
- Price
- PLX $1.76
- ME $3.27
- Analyst Decision
- PLX
- ME Hold
- Analyst Count
- PLX 0
- ME 1
- Target Price
- PLX N/A
- ME $9.40
- AVG Volume (30 Days)
- PLX 382.4K
- ME 322.1K
- Earning Date
- PLX 11-14-2024
- ME 02-05-2025
- Dividend Yield
- PLX N/A
- ME N/A
- EPS Growth
- PLX N/A
- ME N/A
- EPS
- PLX N/A
- ME N/A
- Revenue
- PLX $45,667,000.00
- ME $193,260,000.00
- Revenue This Year
- PLX N/A
- ME $21.93
- Revenue Next Year
- PLX $88.94
- ME $17.31
- P/E Ratio
- PLX N/A
- ME N/A
- Revenue Growth
- PLX N/A
- ME N/A
- 52 Week Low
- PLX $0.82
- ME $2.66
- 52 Week High
- PLX $1.90
- ME $19.34
- Technical
- Relative Strength Index (RSI)
- PLX 62.98
- ME 41.70
- Support Level
- PLX $1.60
- ME $3.03
- Resistance Level
- PLX $1.83
- ME $3.50
- Average True Range (ATR)
- PLX 0.08
- ME 0.33
- MACD
- PLX -0.02
- ME 0.02
- Stochastic Oscillator
- PLX 71.15
- ME 21.05
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.